iFIND TBR: Evidence Scope and Documented Limitations

What Is iFIND TBR?

The iFIND TBR (MTB/RIF) Kit is a molecular diagnostic reagent for detecting Mycobacterium tuberculosis complex DNA and rifampicin resistance mutations. It is manufactured by ROCGene (China) and designed for use with the iFIND automated molecular diagnostics platform.

Manufacturer-Provided Parameters

The following parameters are sourced from manufacturer documentation (brochures, IFU, technical specification sheets) and are not independently verified:

• Detection targets: IS6110, IS1081 (one manufacturer document lists IS1087 — this discrepancy is documented and pending verification), rpoB (81 bp RRDR)
• Limit of detection: MTB identification 10 CFU/mL; rifampicin resistance 100 CFU/mL
• Turnaround time: ≤120 minutes per IFU; 85 minutes per brochure — discrepancy documented
• Amplification method: Nested PCR with molecular beacon multiplex probe melting curve
• Sample types: Sputum (primary); specified for lavage fluid, pleural fluid, pus, CSF, gastric fluid, urine, stool, tissue
• Reagent storage: Lyophilized, 2–28 °C, room temperature transport, stable up to 1 year
• Certification: CE-IVD (manufacturer-provided information)

Documented Discrepancies

Two specific discrepancies have been identified in the manufacturer documentation:

1. IS1081 vs IS1087: One ordering information document references IS1087 instead of IS1081. This may be a typographical error, but it has not been formally clarified by the manufacturer.
2. 85 min vs 120 min turnaround: The IFU states ≤120 minutes, while the brochure states 85 minutes under optimal conditions. The difference may reflect optimal versus worst-case scenarios, but this has not been confirmed.

What Is Not Verified

• No independent peer-reviewed clinical study has been confirmed.
• WHO prequalification has not been claimed or verified.
• FDA approval has not been claimed or verified.
• Independent clinical sensitivity and specificity data are not available.
• Performance characteristics in specific populations (Russian, Indian, African) have not been independently confirmed.

Evidence Level Assignment

All technical parameters listed above are assigned evidence level B (manufacturer-provided, not independently verified). The CE-IVD certification claim is assigned evidence level C (manufacturer-claimed, not independently verified).

No parameter on this platform is presented as evidence level A (independently verified by peer-reviewed clinical study).

Why This Matters

Laboratories evaluating the iFIND TBR kit should:

• Treat all performance claims as manufacturer-provided until independently specified.
• Conduct local validation on their own sample populations.
• Verify regulatory status in their jurisdiction (e.g., ROSZDRAVNADZOR in Russia, CDSCO in India).
• Request the manufacturer to clarify the IS1081/IS1087 discrepancy and the turnaround time discrepancy.

References

All information on this page is derived from manufacturer-provided documents. No independent clinical study is cited because none has been confirmed.